This is a routine commercial leadership change with no new financial guidance or strategic update. Monitor the next quarterly report for any changes in commercial execution or revenue trajectory under the new EVP of Commercial.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 16 $3.86entry
- T+1 · 2mo ago +7.25%α +6.12% · $4.14
- T+5 · 8w ago +3.89%α +1.32% · $4.01
- T+20 · 5w ago +5.70%α +2.52% · $4.08
- T+43 · todayOpen
- T+60 · in 23d Pending
Price Chart
How similar events traded
Executive Summary
Myriad Genetics announced the departure of Chief Commercial Officer Brian Donnelly (effective Sept 16, 2026, with a transition period through Sept 21) and the internal promotion of Vishal Sikri from SVP of Product to EVP of Commercial. The company also reaffirmed its full-year 2026 financial guidance as previously announced on July 30, 2026. This is a routine leadership change with no new financial data or strategic pivot, and the guidance reaffirmation provides no incremental information for traders.
Key Facts
- Chief Commercial Officer Brian Donnelly departed effective September 16, 2026, and will remain as a non-executive employee through September 21, 2026 for transition.
- Vishal Sikri was promoted from SVP of Product to EVP of Commercial, effective September 16, 2026.
- The company reaffirmed its full-year 2026 financial guidance, as announced during the Q2 2026 earnings call on July 30, 2026.
- No financial figures, guidance details, or quantitative data were disclosed in this filing.
Financial Impact
No financial impact disclosed; guidance reaffirmation provides no new quantitative data.
Risk Factors
- Commercial execution risk during leadership transition period (Donnelly departs Sept 21, Sikri steps in immediately).
- No incremental financial data provided, guidance reaffirmation offers no new information for valuation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000899923-26-000079 |
| Exhibit: ex991pressreleasedatedsept.htm | 0000899923-26-000079 |
| Document: 0000899923-26-000079-index-headers.html | 0000899923-26-000079 |
| Document: 0000899923-26-000079-index.html | 0000899923-26-000079 |
| Document: 0000899923-26-000079.txt | 0000899923-26-000079 |
Track record
16 reports on MYGN
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.54% at T+5 after the Oct 20, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry price pending
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $5.67 to $5.72 Now $5.57 −1.76% ▲ +0.88% −0.44% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
- Nov 4, 202612d ago 8-K Mixed 6/10 Entry $6.29 to $5.92 Now $5.57 −11.45% ▼ −5.88% −6.19% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $6.02 to $6.29 Now $5.57 −7.48% ▲ +4.49% +8.89% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $6.63 to $6.67 Now $5.57 −15.99% ▲ +0.60% +0.99% vs SPY
- Oct 20, 202627d ago 8-K Bullish 7/10 Entry $5.54 to $5.57 Now $5.57 +0.54% ▲ +0.54% +0.02% vs SPY
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $3.98 Now $5.57 +39.95% No price data
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $4.20 to $4.08 Now $5.57 +32.62% ▼ −2.86% −2.85% vs SPY
- Sep 16, 20268w ago 8-K Neutral 3/10 Viewing Entry $3.86 to $4.14 Now $5.57 +44.30% ▲ +7.25% +6.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers